Editorial
|
|
|
|
|
Cancer therapy: beware of observation bias
|
|
|
|
Marketing Authorisations
|
|
|
|
|
For lack of a better option
|
|
|
|
|
|
|
|
|
|
No comparison yet with another cytotoxic chemotherapy regimen
|
|
|
|
|
|
|
|
|
|
With more follow-up: stubborn facts
|
|
|
|
|
|
|
|
|
|
No better than sorafenib in kidney cancer
|
|
|
|
|
|
|
|
|
|
Double-blind design is also possible in cancer trials
|
|
|
|
|
|
|
|
|
|
Serious adverse effects but poorly documented efficacy in lung cancer
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Better to avoid using this drug altogether
|
|
|
|
|
|
|
|
|
|
Twice as many vein thromboses as with levonorgestrel
|
|
|
|
|
|
|
|
|
|
|
|
EMA advises against use in children under 8 years
|
|
|
|
|
|
|
|
|
|
Ophthalmological monitoring is needed
|
|
|
|
Reviews
|
|
|
|
|
Thrombolysis for some patients, aspirin in nearly all cases
|
|
|
|
|
|
|
|
|
|
Antithrombotic treatment during the acute phase of ischaemic stroke
|
|
|
|
|
|
|
|
|
|
Aim for 8% or even 9% in frail elderly patients
|
|
|
|
|
|
|
|
|
|
Comparison with sham acupuncture
|
|
|
|
Outlook
|
|
|
|
|
Unambiguous legal definition of euthanasia
|
|
|
|
|
|
|
|
|
|
|
|
Unecessary tests and treatments on the rise
|
|
|
|
|
|
|
|
|
|
A gold-standard emollient
|
|
|
|
|
|